Spice drugs: Cannabinoids as a new designer drugs;Spice drugs: Los cannabinoides como nuevas drogas de diseño

Adicciones

Volumn 21, Issue 3, 2009, Pages 181-186

  Mustata, Cristina ^a,b   Torrens, Marta ^a,c   Pardo, Ricardo ^a,b   Pérez, Clara ^a,b   Schifano, Fabrizio ^c   Deluca, Paolo ^c   Davey, Zoe ^c   Corazza, Ornella ^c   Skutle, Arvid ^c   Flesland, Liv ^c   Di Furia, Lucia ^c   Pagani, Stefania ^c   Minelli, Valentina ^c   Mannonen, Miia ^c   Peltoniemi, Teuvo ^c   Majava, Aino ^c   Scherbaum, Norbert ^c   Siemann, Holger ^c   Van Der Kreeft, Peer ^c   Farré, Magi ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c NONE

Author keywords

CP 47497; HU 210; JWH 018; JWH 073; Spice drugs; Synthetic cannabinoids designer drugs

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 3 [2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL]CYCLOHEXANOL; CANNABINOID DERIVATIVE; CANNABIS; DESIGNER DRUG; DEXANABINOL; HERBACEOUS AGENT; ILLICIT DRUG; JWH 073; UNCLASSIFIED DRUG;

DRUG ABUSE; DRUG MARKETING; DRUG SAFETY; HUMAN; INTERNET; NONHUMAN; REVIEW;

EID: 69549135578     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.227     Document Type: Review

References (23)

1. Buchanan JF, Brown CR. 'Designer drugs'. A problem in clinical toxicology. Med Toxicol Adverse Drug Exp 1988; 3: 1-17.
2. European Monitoring Centre for Drugs and Drug Addiction. Action on new drugs briefing paper: Understanding the Spice phenomenon (a report from an EMCDDA expert meeting, 6 March 2009, Lisbon) Updated version: 9 June 2009. Disponible en: http://www.emcdda.europa.eu/html.cfm/index78154EN.html [consultado el 02/07/09].
3. Stafford GI, Pedersen ME, Van Staden J, Jäger A. Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J. Ethnopharmacology 2008; 119: 513-537.
4. Piggee C. Investigating a not-so-natural high. Anal Chem 2009; 81: 3205-3207.
5. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry 2009; 44: 832-837.
6. Microgram Bulletin, Volume 42, Number 3, March 2009. Disponible en: http://www.usdoj.gov/dea/programs/forensicsci/microgram/mg0309/mg0309.html. [Consultado el 22/06/09].
7. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y. Identification of a Cannabinoid Analog as a New Type of Designer Drug in a Herbal Product. Chem Pharm Bull 2009; 57: 439-441.
8. Ashton JC, Wright JL, McPartland J.M, Tyndall JDA. Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists. Curr Med Chem 2008; 15: 1428-1443.
9. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
10. Huffman JW and Sammy G. Duncan SG. Jr. Synthesis and pharmacology of the 1′,2′-dimethylheptyl 8-THC: exceptionally potent cannabinoids. Bioorganic & Medicinal Chemistry Letters 1997; 7: 2799-2804.
11. Järbe TU, Hiltunen AJ, Mechoulam R. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther 1989; 250: 1000-1005. (Pubitemid 19246712)
12. Ottani A and Giuliani D. HU 210: A Potent Tool for Investigations of the Cannabinoid System. CNS Drug Reviews 2001; 7: 131-145. (Pubitemid 32656298)
13. Weissman A, Milne GM, Melvin LS Jr. Cannabimimetic Activity from CP-47,497, A Derivative of 3-Phenylcyclohexanol. J Pharmacol Exp Ther 1982; 223: 516-523.
14. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992; 260: 201-209.
15. Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor biding. Drug Alcohol Depend 2000; 60: 133-140.
16. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, et al. Structure-Activity Relationships of Indole- and Pyrrole-Derived Cannabinoids. J Pharmacol Exp Ther 1998; 285: 995-1004. (Pubitemid 28277896)
17. Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 1999; 16: 131-143. (Pubitemid 29207717)
18. Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. BrJ Pharmacol 2004; 141: 253-262. (Pubitemid 38250895)
19. Mechoulam R, Fride E, Hanus L, Sheskin T. Anandamide may mediate sleep induction. Nature 1997; 389: 25-26. (Pubitemid 27387679)
20. Muccioli GG, Lambert DM. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem 2005; 12: 1361-1394.
21. European Medicines Agency. London, 23 October 2008 Doc. Ref. EMEA/CHMP/537777/2008. Press release. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Disponible en: http://www.emea.europa.eu/humandoes/PDFs/EPAR/acomplia/53777708en.pdf [consultado el 02/07/09].
22. Mohamad Ben Amar. Cannabinoids in medicine: Areview of their therapeutic potencial. J Ethnopharmacol. 2006.; 105: 1-25.
23. Mc Donald GR, Hudson AL, Dun SMJ, You H, Baker GB, Whittal RM, et al. Bioactive Contaminants Leach from Disposable Laboratory Plasticware. Science 2008; 322: 5903-5912.